USAISR Completes Phase 2 Platelet Study
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Vitrafy Life Sciences Ltd. announces the completion of Phase II testing in a platelet cryopreservation study conducted by the U.S. Army Institute of Surgical Research. The study evaluated both a legacy wash-based protocol and a new no-wash approach, with results indicating potential improvements in cryopreservation standards for platelets. Final analysis and validation are underway, with a report expected to be published later this quarter.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Vitrafy Life Sciences Ltd. on 6ix
Story so far
Earlier from Vitrafy Life Sciences
- FY26 Half Year Results Presentation
- FY26 Appendix 4D and Half Year Report
- Q2 FY26 Quarterly Activities Report and Appendix 4C
- Vitrafy Enters Strategic Commercial Agreement with IMV
- IMV Strategic Partnership Investor Presentation
Later from Vitrafy Life Sciences
- Q3 FY26 Quarterly Activities Report and Appendix 4C
- Final US Army Phase 2 Platelet Results
- Phase 2 USAISR Platelet Results Investor Presentation
- Vitrafy enters a partnership with Vitalant Innovation Center
- Trading Halt
Follow Vitrafy Life Sciences into a list and get an email when it puts out news.
Follow Vitrafy Life Sciences